Press Release

Avacta and Glythera announce collaboration to develop novel, potentially highly potent, drug class

The collaboration will evaluate the use of Avacta’s Affimer technology in combination with Glythera’s PermaLink conjugation chemistry Generation of a new class of highly targeted bio-therapeutics as a potentially superior alternative to antibody drug conjugates (ADCs), a market estimated to be worth $10bn by 2024 Avacta Group plc (AIM: AVCT) (“Avacta” or “the Group”) the developer of Affimer® biotherapeutics and research reagents and Glythera Limited the developer of advanced, stable conjugation chemistries and novel, ultra-potent toxin payloads, today announce that…

Read more>>

Glythera-led consortium wins Industrial Biotechnology Catalyst funding

27th July 2015 Glythera-led consortium wins Industrial Biotechnology Catalyst funding   £248,000 to develop high-throughput glycosylation assay Glythera Limited, the next generation Antibody Drug Conjugate (ADC) company, today announces  that, through a consortium with GlycoSeLect Ltd, specialists in the development and production of recombinant prokaryotic lectins and the Biologics unit of the Centre for Process Innovation (CPI), a UK-based technology innovation centre and part of the High Value Manufacturing Catapult, they have been awarded £248,000 by Innovate UK, the UK…

Read more>>

U.K. Continues to Invest in GMP Manufactured Biologics and Advanced Therapies

  Difficult business requires investment in the right infrastructure and skilled people, as well as developing the right processes for efficient and profitable manufacturing. -       Sue Pearson, Ph.D.    At BioProcessUK’s recent meeting in Liverpool, Steve Bates, CEO of the BioIndustry Association (BIA), the trade body for bioscience companies in the U.K., explained how valuable biologics and vaccine manufacturing is to the country, by stating: “The U.K. medicines manufacturing industry, which includes biologics is one of our leading manufacturing sectors;…

Read more>>